Merck: Interim data for MK-3475 shows survival rate of 81%

Merck announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma that showed an estimated overall survival rate of 81% at one year across all MK-3475 monotherapy doses evaluated. This is the first time overall survival data have been presented from the cohort of 135 patients with advanced melanoma enrolled in Merck’s ongoing Phase IB clinical trial (PN 001) for MK-3475. Researchers presented the findings today in an oral plenary session at the 10th International Congress of the Society for Melanoma Research in Philadelphia.

View Comments (0)